Anapa Biotech A/S is a Copenhagen-based molecular research tools company with novel intellectual property and a first-in-class approach to high throughput nucleic acid assays.
Anapa has developed the MeltPlex® technology for radical improvement of multiplexing of nucleic acid detection to improve PCR-based assays. Despite developments in conventional PCR, the complexity of multiplexed Real Time PCR is still limited due to the lack of sufficient detection channels. Anapa's strategy is to partner our technologies with one or more key molecular diagnostic providers in large markets. The MeltPlex technology provides profound benefits to a large installed user base globally.
Anapa's MeltPlex® technology has wide applicability
Anapa develops molecular tools to enhance the performance of natural nucleic acids in PCR based assays as well as hybridization. Anapa’s technology offers improvement to areas including:
- Human and veterinary diagnostics
- Food and feed quality and safety
- Environmental surveillance
- Scientific research
Anapa offers outstanding resources for a partner
Anapa provides an opportunity to gain:
- Market leadership with MeltPlex®, a unique development for super-multiplexing of high throughput molecular diagnostic tests.
- Unique research tools for rapid nucleic acid detection, up to 20+ in a single tube assay.
- Strong and longlived IP in this space
- Support with specific assay development for our partners
Anapa Biotech A/S is formerly known as QuantiBact A/S. The change in name was concluded in December 2013 as the company entered the phase of commercialization.
QuantiBact A/S was founded in 2002 by Dr. Gorm Lisby and Dr. Henrik Westh from the department of Clinical Microbiology at Hvidovre University Hospital based on a patent application on a method for creation of a novel molecular quick test to detect microorganisms directly in urine in the case of suspected urinary tract infection. In 2004 "proof of technology" was made with financial support from NOVI Innovation A/S and the company was made operational in 2007 with funding from Vecata A/S and Incubation Venture A/S.
The new investors introduced a novel artificial nucleic acid - Twisted Intercalating Nucleic Acid (TINA) and QuantiBact A/S received an exclusive license to use TINA for in-vitro diagnostics. The original patent has subsequently been abandoned, but a number of new patents on molecular tools to enhance the performance of natural nucleic acids in PCR based assays as well as hybridization have been established.
Since December 2012, TINA containing oligonucleotides for research use have been available from Eurofins MWG Synthesis GmbH, Ebersberg, Germany and since June 2013 from Trilink Biotechnologies Inc in San Diego, CA, USA.